The role of target therapy in the treatment of gastrointestinal noncolorectal cancers: Clinical impact and cost consideration

Research output: Contribution to journalReview article

Abstract

Gastrointestinal (GI) tumors are among the leading cause of death in cancer patients worldwide. Particularly, gastric cancer (GC) is the third cause of cancer deaths, whereas esophageal neoplasm is the eighth leading most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also, Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comprehensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches have contributed to improving the outcome in these cancer diseases. During the past few years, remarkable progress in molecular biology of malignancy, the discovery of specific targets, and the resulting development of systemic drugs that block critical kinases and several molecular pathways have all contributed to progress in cancer treatment, also in GI non-colorectal cancer treatment.

Original languageEnglish
Pages (from-to)430-441
Number of pages12
JournalCurrent Cancer Drug Targets
Volume18
Issue number5
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Gastrointestinal Neoplasms
Costs and Cost Analysis
Neoplasms
Therapeutics
Cause of Death
Cholangiocarcinoma
Liver Neoplasms
Esophageal Neoplasms
Pancreatic Neoplasms
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Stomach Neoplasms
Molecular Biology
Anti-Idiotypic Antibodies
Hepatocellular Carcinoma
Adenocarcinoma
Phosphotransferases
Monoclonal Antibodies
Clinical Trials
Drug Therapy

Keywords

  • Clinical aspects
  • Costs
  • Gastrointestinal cancers
  • Metastases
  • Prognostic factors
  • Target therapy
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

@article{39f8732d22f8463a9627b1a31e130767,
title = "The role of target therapy in the treatment of gastrointestinal noncolorectal cancers: Clinical impact and cost consideration",
abstract = "Gastrointestinal (GI) tumors are among the leading cause of death in cancer patients worldwide. Particularly, gastric cancer (GC) is the third cause of cancer deaths, whereas esophageal neoplasm is the eighth leading most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also, Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comprehensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches have contributed to improving the outcome in these cancer diseases. During the past few years, remarkable progress in molecular biology of malignancy, the discovery of specific targets, and the resulting development of systemic drugs that block critical kinases and several molecular pathways have all contributed to progress in cancer treatment, also in GI non-colorectal cancer treatment.",
keywords = "Clinical aspects, Costs, Gastrointestinal cancers, Metastases, Prognostic factors, Target therapy, Treatment",
author = "Massimiliano Berretta and Carmela Romano and {Di Francia}, Raffaele and {De Diviitis}, Chiara and Vincenzo Canzonieri and Michele Caraglia and Gaetano Facchini and Guglielmo Nasti",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1568009617666170208162058",
language = "English",
volume = "18",
pages = "430--441",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - The role of target therapy in the treatment of gastrointestinal noncolorectal cancers

T2 - Clinical impact and cost consideration

AU - Berretta, Massimiliano

AU - Romano, Carmela

AU - Di Francia, Raffaele

AU - De Diviitis, Chiara

AU - Canzonieri, Vincenzo

AU - Caraglia, Michele

AU - Facchini, Gaetano

AU - Nasti, Guglielmo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Gastrointestinal (GI) tumors are among the leading cause of death in cancer patients worldwide. Particularly, gastric cancer (GC) is the third cause of cancer deaths, whereas esophageal neoplasm is the eighth leading most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also, Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comprehensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches have contributed to improving the outcome in these cancer diseases. During the past few years, remarkable progress in molecular biology of malignancy, the discovery of specific targets, and the resulting development of systemic drugs that block critical kinases and several molecular pathways have all contributed to progress in cancer treatment, also in GI non-colorectal cancer treatment.

AB - Gastrointestinal (GI) tumors are among the leading cause of death in cancer patients worldwide. Particularly, gastric cancer (GC) is the third cause of cancer deaths, whereas esophageal neoplasm is the eighth leading most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also, Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comprehensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches have contributed to improving the outcome in these cancer diseases. During the past few years, remarkable progress in molecular biology of malignancy, the discovery of specific targets, and the resulting development of systemic drugs that block critical kinases and several molecular pathways have all contributed to progress in cancer treatment, also in GI non-colorectal cancer treatment.

KW - Clinical aspects

KW - Costs

KW - Gastrointestinal cancers

KW - Metastases

KW - Prognostic factors

KW - Target therapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85048983925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048983925&partnerID=8YFLogxK

U2 - 10.2174/1568009617666170208162058

DO - 10.2174/1568009617666170208162058

M3 - Review article

VL - 18

SP - 430

EP - 441

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 5

ER -